Axsome Therapeutics, Inc. (AXSM) Reaches $3.30 Yearly Low; 6 Analysts Covering Pembina Pipeline (TSE:PPL)

January 14, 2018 - By Steve Bissell

Among 7 analysts covering Pembina Pipeline Corporation (TSE:PPL), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Pembina Pipeline Corporation had 35 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Pembina Pipeline Corporation (TSE:PPL) earned “Outperform” rating by IBC on Tuesday, August 11. GMP Securities initiated the stock with “Buy” rating in Monday, June 27 report. Scotia Capital maintained the stock with “Outperform” rating in Friday, February 24 report. On Monday, August 10 the stock rating was maintained by TD Securities with “Buy”. RBC Capital Markets maintained Pembina Pipeline Corporation (TSE:PPL) on Friday, November 20 with “Outperform” rating. The firm has “Outperform” rating given on Friday, August 7 by Scotia Capital. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, April 4. As per Friday, February 24, the company rating was maintained by RBC Capital Markets. The stock of Pembina Pipeline Corporation (TSE:PPL) earned “Outperform” rating by National Bank Canada on Friday, November 20. Raymond James maintained it with “” rating and $43 target in Monday, June 6 report. See Pembina Pipeline Corporation (TSE:PPL) latest ratings:

08/12/2017 Broker: JP Morgan Rating: Old Target: $53.00 New Target: $55.00 Target Up
01/12/2017 Broker: National Bank Canada Rating: Sector Perform Old Target: $51.00 New Target: $52.00 Target Up

The stock of Axsome Therapeutics, Inc. (NASDAQ:AXSM) hit a new 52-week low and has $3.00 target or 9.00% below today’s $3.30 share price. The 8 months bearish chart indicates high risk for the $83.98 million company. The 1-year low was reported on Jan, 14 by Barchart.com. If the $3.00 price target is reached, the company will be worth $7.56M less. The stock decreased 2.94% or $0.1 during the last trading session, reaching $3.3. About 1.34M shares traded or 294.88% up from the average. Axsome Therapeutics, Inc. (NASDAQ:AXSM) has declined 59.08% since January 14, 2017 and is downtrending. It has underperformed by 75.78% the S&P500.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system disorders. The company has market cap of $83.98 million. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It currently has negative earnings. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain.

Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Axsome Therapeutics had 3 analyst reports since December 14, 2015 according to SRatingsIntel. The company was initiated on Tuesday, December 15 by Cantor Fitzgerald. As per Monday, October 3, the company rating was initiated by Brean Capital. The stock of Axsome Therapeutics, Inc. (NASDAQ:AXSM) earned “Buy” rating by Ladenburg Thalmann on Monday, December 14.

The stock decreased 0.23% or $0.1 during the last trading session, reaching $44.17. About 551,044 shares traded. Pembina Pipeline Corporation (TSE:PPL) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Steve Bissell







Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: